关键信息
-
基因名
STEAP1B
- 应用
-
种属
Human
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q6NZ63
-
表达区间
1-245aa
-
分子量
30.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
STEAP1B (Six-Transmembrane Epithelial Antigen of the Prostate 1B) is a member of the STEAP family, which has garnered attention due to its potential role in cancer biology, particularly in prostate cancer. The STEAP proteins, characterized by multiple transmembrane domains, are involved in various cellular processes, including iron homeostasis, cell adhesion, and tumor progression. STEAP1B is believed to contribute to tumorigenesis by influencing the cellular microenvironment and modulating immune responses. Recent studies have indicated that STEAP1B may be a promising biomarker for prostate cancer diagnosis and prognosis. Additionally, the development of recombinant STEAP1B protein allows for in-depth investigation of its functional properties and interactions within the tumor microenvironment. This research leverages advanced techniques in molecular biology and protein engineering to produce STEAP1B in a recombinant form, enabling researchers to study its enzymatic activities, structural features, and potential as a therapeutic target. Understanding the mechanisms by which STEAP1B influences cancer cell behavior could provide insights into novel treatment strategies and contribute to the advancement of targeted therapies in oncology. Overall, the study of STEAP1B recombinant protein holds significant promise for enhancing our understanding of prostate cancer and improving clinical outcomes for patients.
